Financial Implications of COVID-19 Polymerase Chain Reaction Tests on Independent Laboratories

During the COVID-19 pandemic, independent laboratories provided critically needed polymerase chain reaction (PCR) tests (Current Procedure Terminology Code: 87635) to identify positive COVID-19 patients. The Families First and Coronavirus Relief Act and CARES Act require commercial insurance plans to cover COVID-19 testing costs without any cost-sharing for patients, but do not set the price.1,2 Prior research has examined the variation in charges for PCR tests in laboratories.3 However, their financial return from COVID-19 testing remains unexplored. Using the unique taxation data from Hawaii, we analyzed how the COVID-19 pandemic affected the revenue and profitability of independent laboratories.

Halliday, T., Tan, C., Juarez, R. et al. Financial Implications of COVID-19 Polymerase Chain Reaction Tests on Independent Laboratories. Journal of General Internal Medicine (2022).

Leave a Comment

Your email address will not be published. Required fields are marked *

The University of Hawaii Economic Research Organization (UHERO) welcomes online comments to stories that are posted on our website or social media pages. Comments are intended to be a forum for open, respectful, and family-friendly discussion. UHERO reserves the right to remove anything posted on our website or social media pages that is deemed inappropriate. All comments are moderated and will therefore have a delayed post time.
Some guidelines (not an exhaustive list) we use when moderating/approving comments include:

  • Do not bully, intimidate, or harass any user.
  • Do not post content that is hateful, threatening or wildly off-topic; or do anything unlawful, malicious, discriminatory or defamatory.
  • Observe confidentiality laws at all times.
  • Do not post spam or advertisements.
  • Observe fair use, copyright and disclosure laws.
  • Do not use vulgar language or profanity.

UHERO may amend this policy from time to time.